Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €414.8 million, within guidance 2023 and year-to-date key updates : Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A. Achieved encouragi...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.
Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area.
Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos' transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addr...
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM). This is Galapa...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.